Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Isentress Approved for All Adult HIV Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Isentress in combination therapy has less effect on lipid levels than standard of care Sustiva-based therapy in HIV treatment naïve patients, study shows.

You may also be interested in...



Glaxo and Pfizer Form HIV Venture, But A Spin-Off Could Be In The Wings

In a bid to patch over their respective weaknesses in the HIV marketplace, GlaxoSmithKline and Pfizer announced April 16 they are forming a jointly owned company combining their portfolios of existing and developing drugs

Gilead Positioned To Benefit From Potential HIV Guidelines Change

Emerging data on initiating anti-retroviral treatment earlier in HIV patients could broaden the treatment-naïve market.

Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales

Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel